Use of Biperiden for the Prevention of Post-traumatic Epilepsy

Traumatic Brain Injury Clinical Trial

Official title:

Use of Biperiden as a Disease Modifying Agent After Traumatic Brain Injury: a Placebo Controlled, Randomized, Double Blind Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01048138
• Other study ID #: CEP0560/05
• Status: Terminated
• Phase: Phase 3
• Start date: January 31, 2018
• Est. completion date: December 2, 2022

Study information

• Verified date: January 2023
• Source: Federal University of São Paulo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.

Description:

Treatment with biperiden should be initiated in the first 12 hours after trauma as means to avoid the epileptogenic process. The treatment will be repeated every 6 hours for 10 consecutive days. The efficacy of biperiden as an antiepileptogenic drug will be established by analyzing the development of PTE between the biperiden and placebo groups. Several patients' aspects (clinical, electroencephalography, brain imaging, genetic and behavioral data) will be monitored for two year follow-up to unravel the mechanisms by which biperiden exerts its actions on epileptogenesis. The investigators are already at the early stages of patient's recruitment using the available resources.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 123
• Est. completion date: December 2, 2022
• Est. primary completion date: December 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• between 18 and 75 year of age

• patients with a diagnosis of acute TBI admitted to an emergency unit within 12 hours of the accident, regardless of the accident

• brain CT scan with signs of acute intraparenchymatous contusion

• signed informed consent (possibly by a relative)

Exclusion Criteria:

• malignant neoplasia and other severe comorbidities

• neurodegenerative disorders

• previous cerebrovascular accident

• record of convulsive seizures or use of anti-epileptic medication

• pregnancy

• concomitant use of the other anticholinergic medications

• presence of any factor that may contraindicate the use of biperiden

• participation in other clinical trial

• alcohol intoxication will not lead to exclusion of the subject.

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Traumatic Brain Injury

Intervention

Drug:
• Biperiden Lactate
5mg IV(in the vein)every 6 hours for 10 days
• Placebo
5mg IV(in the vein)every 6 hours for 10 days

Locations

Country	Name	City	State
Brazil	Federal University of São Paulo	Sao Paulo

Sponsors (2)

Lead Sponsor	Collaborator
Federal University of São Paulo	University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Electroencephalogram Analysis: Presence of Epileptiform Discharges	Given the requirement of specific adjustments in the EEG recording apparatus (10 KHz sampling rate, high-pass filter above 80 Hz for ripples and 250 Hz for fast ripples), only a subset of patients will be included in this outcome. EEG will be continuously registered during the first 10 days after TBI, weekly until hospital discharge and at specified time frames after TBI. The presence of high frequency oscillations (ripples and fast ripples) will be investigated.	during first 10 days after TBI and 1, 3, 6, 9, 12, 18 and 24 months after TBI
Other	Cognitive Assessments - Wechsler Adult Intelligence Scale (WAIS) - III	Cognitive effects of the biperiden therapy will be assessed to demonstrate the efficacy and safety of this medicine in face of its possible cognitive implications. The instruments selected to assess those are tests of the Wechsler Adult Intelligence Scale (WAIS) - III. The WAIS-III returns scores on four separate indexes of adult intelligence, the Perceptual Reasoning Index, the Verbal Comprehension Index, the Working Memory Index and the Processing Speed Index. Scores will be calculated on each of the 4 indices and then combined to create a Full-Scale IQ. The WAIS-III is normed so that 100 is the median score for the adult population (score ranges: 120-129= superior, 110-119= high average, 90-109=average, 80-89= low average, 71-80= borderline intellectual functioning, 50-70= moderate retardation, below 50= severe retardation. The battery of tests will be applied at specific time frames and results will be compared.	6, 12 and 24 months after hospital discharge
Other	Quality of Life assessments - European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L), EQ-VAS	The Brazilian version of the EQ-5D-3L and EQ-VAS questioner will be used to assess health-related quality of life (HRQoL), 24 months after TBI. It consists of a questionnaire covering five dimensions of HRQoL (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a visual analog scale (VAS). The descriptive system defines 243 different health states.	24 month after TBI
Other	Blood sampling biomarkers - Expression of miRNAs	Alterations in expression of miRNAs will be assayed in blood samples during treatment with biperiden, or 18 months after trauma. Patterns of changes in the miRNA levels will be compared between the groups of patients that developed post-traumatic epilepsy or did not develop epilepsy.	10 days or 18 months after TBI
Other	Blood sampling biomarkers - Expression of the ApoE?4 allele	To investigate the expression of the ApoE?4 allele in TBI patients, and its correlation with post-traumatic epilepsy development and the biperiden treatment efficacy to prevent epilepsy, RFLP-PCR will be assayed in blood samples of TBI patients. The genotyping reactions will be performed blinded to clinical features. The presence of the ApoE?4 allele will be correlated with the incidence of seizures in the follow up assessments after TBI.	10 days or 18 months after TBI
Other	Blood sampling biomarkers - Expression of inflammatory cytokines	To verify whether cytokines are differently involved on PTE development, we will perform multi-analyte protein profile in blood plasma samples collected during treatment with biperiden. Simultaneous measuring of different proteins in plasma will be performed. The concentration of each analyte will be normalized to the total protein concentration and presented as a proportion of specific proteins in picograms (pg) per microgram (µg) of total protein. Patterns of protein expression will be correlated with the incidence of seizures in the follow up assessments after TBI.	10 days after TBI
Other	Brain Activity Biomarkers - Presence of high frequency oscillations	Given the requirement of specific adjustments in the EEG recording apparatus (10 KHz sampling rate, high-pass filter above 80 Hz for ripples and 250 Hz for fast ripples), only a subset of patients will be included in this outcome. EEG will be continuously registered during the first 10 days after TBI, weekly until hospital discharge and at specified time frames after TBI. The presence of high frequency oscillations (ripples and fast ripples) will be investigated.	during first 10 days after TBI and 1, 3, 6, 12, 18 and 24 months after TBI
Other	Brain Activity Biomarkers - Presence of cortical spreading depression	Given the requirement of specific adjustments in the EEG recording apparatus (e.g., direct current [DC] recording) to detect cortical spreading depression, a subset of patients will be EEG continuously registered during the first 10 days after trauma with other recording specifications. The presence of cortical spreading depression activity will be investigated.	during first 10 days after TBI
Primary	Clinical Outcome: Indidence of post-traumatic epilepsy	The incidence of seizures will be evaluated starting immediately after TBI and continuously during the hospitalization period and after hospital discharge during the two year follow up period. Patients and their relatives will be asked to maintain a diary of seizures, and thus record all seizures with detailed descriptions of each event. The recordings will be evaluated in each patient visit. Seizures incidence will be compared between placebo and biperiden-treated patients.	24 months after TBI
Secondary	Frequency of seizures	The frequency of seizures will be counted starting immediately after TBI and continuously during the hospitalization period and after hospital discharge during the two year follow up period. Frequency of seizure will be compared between placebo and biperiden-treated patients.	24 months after TBI
Secondary	Mortality and adverse effects	The incidence of death and adverse effects will be counted starting immediately after TBI and continuously during the hospitalization period and after hospital discharge during the two year follow up period. Incidence of death and adverse effects will be compared between placebo and biperiden-treated patients.	24 months after TBI